Table 2.
Reimbursement status for oncologic and metabolic drugs.
| Drugs | Reimbursement status | England | Scotland | France | Spain | Poland | Germany | All |
|---|---|---|---|---|---|---|---|---|
| Oncologic | Not Reimbursed | 15 (27.8%) | 15 (27.8%) | 11 (20.4%) | 17 (31.5%) | 37 (68.5%) | 6 (11.1%) | (31.2%) |
| Reimbursed | 39 (72.2%) | 39 (72.2%) | 43 (79.6%) | 37 (68.5%) | 17 (31.5%) | 48 (88.9%) | (68.8%) | |
| Metabolic | Not Reimbursed | 6 (18.2%) | 6 (18.2%) | 12 (36.4%) | 14 (42.4%) | 26 (78.8%) | 1 (3.0%) | (32.8%) |
| Reimbursed | 27 (81.8%) | 27 (81.8%) | 21 (63.6%) | 19 (57.6%) | 7 (21.2%) | 32 (97.0%) | (67.2%) |